Conference: October 19-20 | In-Person

In today’s dynamic healthcare environment, Real-World Evidence (RWE) is no longer confined to post-market safety. It is reshaping the entire product lifecycle, from early development through regulatory decision-making and reimbursement.

DIA’s 2026 Real-World Evidence Conference will convene global regulators, industry leaders, data scientists, and policy experts to examine the latest developments shaping the field. The program will feature regulatory perspectives from agencies including the FDA, EMA, and other global authorities, alongside discussions on data quality, governance, and evolving standards for the use of real-world data in regulatory and clinical decision-making.

Sessions will highlight emerging approaches to generating and applying real-world evidence, including advances in data science, study design, and collaborative research models. Discussions will also consider the opportunities and challenges associated with using diverse data sources and analytical tools to support evidence generation across healthcare and regulatory environments.

Through case studies, expert panels, and collaborative discussions, participants will gain practical insights into generating credible, regulatory-relevant evidence that supports better decisions, fosters innovation, and ultimately improves patient outcomes.

While we develop our 2026 agenda, please take a moment to review the 2025 final agenda